Elektra Health Real Customer Outcomes: An Independent Analysis

What Is Elektra Health and How Does the Model Work?

Elektra Health is a direct-to-patient telehealth company focused entirely on menopause care. Unlike general-purpose telehealth platforms, every clinician on the platform has completed additional menopause training or holds menopause specialist credentials. New patients complete a detailed symptom intake, schedule a video visit with a clinician, and receive a personalized care plan that may include prescription therapy, supplement guidance, and lifestyle recommendations.

The Insurance and Cash-Pay Structure

Elektra accepts a growing list of commercial insurance plans. For patients without coverage, initial consultations run roughly $250 to $350, with follow-up visits priced lower. This is meaningfully less expensive than seeing an out-of-network gynecologist at a hospital system, where a new-patient menopause consultation can exceed $500 in many metro markets.

Prescriptions are sent to the patient's pharmacy of choice, including mail-order options. The platform does not operate a proprietary compounding pharmacy, which distinguishes it from some competitors that bundle compounded hormone products directly into a subscription fee.

What the Intake Process Looks Like

Patients fill out a structured digital questionnaire covering symptom severity, menstrual history, cardiovascular risk factors, personal and family cancer history, and prior hormone use. Clinicians use this intake to screen for contraindications before the visit, which reduces consultation time spent on basic history-taking and allows for a more targeted conversation about treatment options.

Does Hormone Therapy Actually Work? The Evidence Behind Elektra's Core Treatments

Before evaluating any platform's outcomes, the treatments it prescribes must be evaluated against the clinical literature. Elektra Health's primary tool is menopausal hormone therapy (MHT), and the evidence base for MHT is among the strongest in women's health.

Vasomotor Symptom Relief

The 2023 position statement of the North American Menopause Society (NAMS) states: "Hormone therapy is the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [1] That single sentence summarizes decades of randomized controlled trial data.

The ELITE trial (N=643), published in the New England Journal of Medicine, showed that oral estradiol initiated within six years of menopause slowed progression of subclinical atherosclerosis (carotid intima-media thickness 0.0078 mm/year in the treatment group vs. 0.0044 mm/year in placebo, P<0.001 for the timing-of-initiation analysis). [2] This supports the "timing hypothesis" that MHT cardioprotection depends on when therapy starts relative to menopause onset.

Bone Protection

The Women's Health Initiative (WHI) randomized 16,608 postmenopausal women and found that combined conjugated equine estrogen plus medroxyprogesterone acetate reduced hip fracture risk by 34% (hazard ratio 0.66, 95% CI 0.45 to 0.98). [3] More modern transdermal formulations, which Elektra clinicians preferentially prescribe, carry a lower venous thromboembolism risk than oral conjugated estrogen, per a 2019 BMJ analysis by Vinogradova et al. (adjusted OR 0.93 for transdermal vs. 1.58 for oral estrogen). [4]

Non-Hormonal Options Elektra Also Prescribes

For patients with contraindications to estrogen, Elektra clinicians prescribe FDA-approved non-hormonal options. Fezolinetant (brand name Veozah), approved by the FDA in May 2023, targets neurokinin B signaling and reduced moderate-to-severe vasomotor symptom frequency by 59% at week 12 in the SKYLIGHT-1 trial. [5] Paroxetine 7.5 mg (Brisdelle) is the only SSRI with an FDA indication specifically for vasomotor symptoms. These options matter because a meaningful proportion of menopause patients cannot safely use systemic hormones.

Real Customer Outcomes: What Patients Actually Report

No large independent RCT has evaluated Elektra Health specifically as a platform. That absence is standard for telehealth companies and does not itself indicate a problem. The honest answer is that platform-level outcome data comes from three sources: patient review aggregators, published telehealth menopause research (not Elektra-specific), and the quality of clinical protocols the platform applies.

What Review Aggregators Show

Across Trustpilot, Google Reviews, and app store ratings as of early 2025, Elektra Health holds an average rating between 4.3 and 4.7 out of 5 stars across several hundred reviews. Recurring themes in positive reviews include clinicians spending more than 30 minutes on initial visits (unusual in primary care), prescriptions being written at the first visit rather than after a waitlist referral, and patients feeling heard after years of having symptoms dismissed. Negative reviews center on insurance claim processing delays and difficulty reaching the administrative team outside of scheduled visits.

These are self-selected reports and cannot be interpreted as clinical outcome data. However, the pattern of complaints (administrative friction rather than clinical quality concerns) is a meaningful signal.

Published Telehealth Menopause Research

A 2021 study in Menopause (journal of NAMS) found that patients receiving menopause care via synchronous telehealth reported equivalent symptom improvement on the Menopause Rating Scale compared to in-person care at 12 weeks, with no statistically significant difference in patient satisfaction (P=0.42). [6] Elektra's model is synchronous video-based, which matches the studied modality.

A 2022 survey published in JAMA Internal Medicine found that 73% of women with bothersome vasomotor symptoms had never been offered hormone therapy by their primary care provider, despite having no documented contraindications. [7] This gap is Elektra's core clinical rationale: specialist access increases appropriate prescribing.

The HealthRX Menopause Telehealth Assessment Framework

When evaluating any menopause telehealth platform, four dimensions predict patient outcomes more reliably than brand reputation alone:

1. Clinician menopause training. NAMS Certified Menopause Practitioner (NAMS CMP) credential or equivalent. Elektra requires documented menopause-specific training; not all telehealth platforms do.
2. Formulary breadth. Can the platform prescribe transdermal estradiol patches, vaginal DHEA (prasterone), micronized progesterone (Prometrium), and non-hormonal agents like fezolinetant? Narrow formularies force clinicians into suboptimal substitutions.
3. Contraindication screening. Structured intake covering thromboembolism history, hormone-receptor-positive cancer history, and active liver disease. Elektra's digital intake covers these domains.
4. Follow-up cadence. The Endocrine Society recommends reassessment at 3 months after initiating MHT to evaluate symptom response and tolerability. [8] Platforms with no structured follow-up pathway leave patients without dose-adjustment support.

Elektra scores well on dimensions 1, 2, and 3. Patient reports suggest follow-up scheduling (dimension 4) is available but requires patient initiation rather than proactive outreach, which is a design gap worth noting.

Is Elektra Health Legit? Credentials and Regulatory Standing

Yes. Elektra Health operates as a licensed telehealth medical practice. Prescribing clinicians hold active state licenses in the states where they see patients. The platform complies with applicable state telehealth prescribing laws, which vary considerably across the U.S.

Clinician Credentials

Elektra's clinical team is composed of OB-GYNs and advanced practice providers. Many hold or are working toward the NAMS Certified Menopause Practitioner designation, which requires passing a 150-question examination covering MHT pharmacology, cardiovascular risk stratification, and genitourinary syndrome of menopause.

Prescribing Compliance

The FDA's prescribing guidelines for estrogen-containing products require that clinicians prescribe at the lowest effective dose for the shortest duration consistent with treatment goals. [9] Elektra's clinical protocols align with this standard. The platform does not prescribe bioidentical compounded hormone products as a first-line option, preferring FDA-approved formulations with established safety profiles, which is consistent with NAMS guidance. [1]

Privacy and Data Handling

Elektra Health is subject to HIPAA. Patient health information collected through the intake process and video visits is protected health information under 45 CFR Part 164. The company's privacy policy specifies that data is not sold to third-party advertisers.

Elektra Health vs. Alternatives: A Direct Comparison

Several other platforms operate in the menopause telehealth space. The right choice depends on your insurance situation, prescription needs, and preference for clinical model.

Elektra Health vs. Midi Health

Midi Health also focuses exclusively on menopause. Both accept insurance. Midi has a somewhat larger network of states and more aggressively markets its insurance-first model. Elektra's brand positioning emphasizes education alongside clinical care, including a "school" component with webinars and community resources. For patients who want peer support alongside clinical visits, Elektra's model adds that layer. For patients who want the lowest possible out-of-pocket cost with minimal extras, Midi's pricing is comparable.

Elektra Health vs. Alloy Health

Alloy operates on a subscription model and ships compounded or commercial hormone products directly. It does not accept insurance. For a patient with good insurance coverage, Elektra's insurance acceptance makes it considerably less expensive over six to twelve months. Alloy's compounding-first model may appeal to patients who have not responded to standard commercial formulations, but compounded hormones lack FDA approval and carry manufacturing consistency risks that FDA-approved products do not.

Elektra Health vs. Primary Care or OB-GYN

The 2022 JAMA Internal Medicine finding that 73% of eligible women were never offered HRT by their primary care provider [7] illustrates why specialist telehealth exists. An established OB-GYN who manages menopause well is likely the gold standard, but wait times for new-patient gynecology appointments in the U.S. Average 26.4 days nationally (Merritt Hawkins 2022 survey data), with many markets exceeding 60 days. Elektra's 1 to 2 week wait time is a practical advantage for symptomatic patients.

What Elektra Health Prescribes: A Formulary Overview

Elektra clinicians have access to the full range of FDA-approved menopause therapies. Below is a structured overview.

Systemic Hormone Therapy

• Transdermal estradiol (patches: Vivelle-Dot, Climara; gels: Divigel, EstroGel; spray: Evamist). Preferred over oral for patients with any elevated clotting risk.
• Oral estradiol (Estrace 0.5 mg, 1 mg, 2 mg). Lower cost than patches; appropriate for patients with low VTE risk.
• Micronized progesterone (Prometrium 100 mg, 200 mg). Required for endometrial protection in women with an intact uterus. Prometrium carries a lower breast cancer risk signal than synthetic progestins in observational data (E3N cohort, N=80,377). [10]
• Combined products (Combipatch, Bijuva) for patients who prefer a single product.

Local / Vaginal Therapy

• Vaginal estradiol cream and ring (Estrace cream, Estring). Low systemic absorption; safe in most patients including many with hormone-sensitive cancer history per ACOG guidance. [11]
• Ospemifene (Osphena 60 mg oral) for dyspareunia without vaginal application.
• Prasterone (Intrarosa vaginal insert). DHEA-based; FDA approved 2016.

Non-Hormonal Prescription Options

• Fezolinetant (Veozah 45 mg). FDA approved May 2023. Liver function monitoring required at baseline and 3, 6, and 9 months.
• Paroxetine 7.5 mg (Brisdelle). Note: contraindicated with tamoxifen due to CYP2D6 inhibition.
• Gabapentin off-label for vasomotor symptoms; evidence modest (Cochrane review found 2.05 fewer hot flashes per day vs. Placebo, 95% CI 1.64 to 2.46). [12]

Cost Breakdown: What You Will Actually Pay

Understanding total cost requires separating platform fees from pharmacy costs.

Platform Fees

Cash-pay patients typically pay $250 to $350 for an initial 45-to-60-minute consultation. Follow-up visits run $100 to $175. Patients with in-network insurance pay their standard specialist copay, which for most PPO plans is $40 to $75.

Prescription Costs

Transdermal estradiol patches (generic Vivelle-Dot) cost approximately $30 to $60 per month at GoodRx pricing. Micronized progesterone 200 mg runs $20 to $45 per month generic. Fezolinetant 45 mg is brand-only and costs approximately $550 per month without insurance; most commercial plans with Part D or commercial drug coverage pay a portion.

A patient with insurance covering both the visit and the pharmacy benefit might pay $40 to $120 per month total for a managed menopause regimen. A cash-pay patient on transdermal estradiol plus progesterone might spend $350 for the initial visit and $60 to $100 monthly thereafter.

Who Is (and Is Not) a Good Fit for Elektra Health?

Good Fit

Women experiencing moderate-to-severe vasomotor symptoms (more than 7 hot flashes per day per NAMS severity thresholds) who have not received an adequate evaluation from a primary care provider. Women in perimenopause with irregular cycles and mood changes who want a specialist rather than a general practitioner. Postmenopausal women who stopped HRT years ago and want to discuss restarting with a clinician who understands current evidence.

Less Ideal Fit

Patients with complex comorbidities requiring coordinated multi-specialist care (active breast cancer treatment, recent cardiovascular event) need in-person subspecialty management, not telehealth. Patients who need gynecologic exams, such as evaluation of abnormal uterine bleeding or a new pelvic mass, cannot complete those assessments via video. Elektra is not a substitute for an annual well-woman exam.

The Bottom Line on Clinical Safety

MHT is safe for most healthy women under 60 or within 10 years of menopause onset, per the NAMS 2023 position statement. [1] The elevated breast cancer risk associated with combined HRT in the original WHI analysis has been substantially recontextualized: the Women's Health Initiative observational follow-up showed that estrogen-alone therapy in women who had a hysterectomy was associated with a reduced breast cancer risk at 18 years (HR 0.78, 95% CI 0.65 to 0.93). [13] Risks are real but individualized; a clinician-led risk stratification conversation is exactly what Elektra's model is designed to provide.

Elektra's refusal to default to compounded hormones is a patient safety feature, not a limitation. FDA-approved products have consistent dosing; compounded preparations do not undergo the same quality-control testing, and the FDA has issued multiple warning letters to compounding pharmacies for potency and sterility failures.